Table 1.
Characteristic | All patients | BiV | MPP | P (BiV vs. MPP) |
---|---|---|---|---|
Sample size, n (%) | 142 (100.0%) | 69 (48.6%) | 73 (51.4%) | |
Male, n (%) | 96/142 (67.6%) | 48/69 (69.6%) | 48/73 (65.8%) | 0.720 |
Age, year | 61.2 [52.3, 67.9] | 59.6 [52.1, 67.0] | 62.1 [52.3, 69.4] | 0.251 |
NYHA, n (%) | 0.186 | |||
I | 0/142 (0.0%) | 0/69 (0.0%) | 0/73 (0.0%) | |
II | 27/142 (19.0%) | 16/69 (23.2%) | 11/73 (15.1%) | |
III | 107/142 (75.4%) | 50/69 (72.5%) | 57/73 (78.1%) | |
IV | 8/142 (5.6%) | 3/69 (4.3%) | 5/73 (6.8%) | |
Ischemic, n (%) | 47/142 (33.1%) | 21/69 (30.4%) | 26/73 (35.6%) | 0.593 |
Hypertension, n (%) | 81/142 (57.0%) | 34/69 (49.3%) | 47/73 (64.4%) | 0.090 |
Diabetes, n (%) | 74/142 (52.1%) | 39/69 (56.5%) | 35/73 (47.9%) | 0.319 |
QRS duration, ms | 158.0 [150.0, 170.0] | 158.0 [150.0, 170.0] | 160.0 [150.0, 172.3] | 0.434 |
LVESV, mL | 135.0 [102.0, 200.0] | 140.0 [102.0, 191.0] | 130.0 [103.0, 206.0] | 1.000 |
LVEDV, mL | 185.5 [148.0, 265.0] | 185.0 [163.8, 250.0] | 188.0 [145.0, 274.0] | 0.920 |
LVSV, mL | 50.0 [39.0, 61.0] | 50.0 [40.0, 60.3] | 49.0 [37.3, 63.5] | 0.612 |
LVEF, % | 25.8 [21.2, 33.3] | 25.7 [21.7, 32.5] | 26.0 [21.1, 33.6] | 0.922 |
LV lead location [base-apex], n (%) | 0.121 | |||
Basal | 29/142 (20.4%) | 19/69 (27.5%) | 10/73 (13.7%) | |
Medial | 108/142 (76.1%) | 48/69 (69.6%) | 61/73 (82.2%) | |
Apical | 5/142 (3.5%) | 2/69 (2.9%) | 3/73 (4.1%) | |
LV lead location [ant.-post.], n (%) | 0.145 | |||
Anterior | 1/142 (0.7%) | 1/69 (1.4%) | 0/73 (0.0%) | |
Lateral | 56/142 (39.4%) | 33/69 (47.8%) | 23/73 (31.5%) | |
Postero-lateral | 83/142 (58.5%) | 34/69 (49.3%) | 49/73 (67.1%) | |
Posterior | 2/142 (1.4%) | 1/69 (1.4%) | 1/73 (1.4%) |
P values demonstrate differences between BiV and MPP groups